Can Damaged Sperm Lead To Pregnancy Complications?
Pregnancy is usually a time of happiness and hope, but it also brings in the unexpected. While there is much talk placed on the health of the expectant mother, the quality sperm coming from the father could dramatically change the outcome of pregnancy. The latest study suggests the risks of sperm DNA damage, even increasing the risks of complications preeclampsia and birth prematurity.
In a groundbreaking research study conducted by scientists from Lund University in Sweden, scientists discovered that DNA damage in sperm increases the risk almost up to double that of preeclampsia, this is a dangerous condition that may arise during pregnancies characterized by high blood pressure. In addition, DNA anomalies also increase the risk of premature births, and this further entails increased related adverse health outcomes for infants born through such conditions.
The next step would be to find out which group of men respond best to methods to prevent and treat sperm DNA damage, and to test these methods to prevent pregnancy complications," said Dr. Amelie Stenqvist, a lecturer at Lund University. According to this study, a significant message is put forward that paternal health assumes an important role in a successful pregnancy.
It focused its research on men, specifically whose sperm contained high levels of DNA fragmentation. For instance, some 20% to 30% of babies born via in vitro fertilization have fathers whose sperm contains damaged DNA. The DNA fragmentation index, an indicator to assess the percentage of DNA damage in sperm, indicated that when the percentage of sperm with a DFI above 30% was observed, they had almost no chance of resulting in natural conception. Even a DFI greater than 20% showed that the chances of getting pregnant are highly risky as the risk factor for pregnancy complications like preeclampsia is much high.
Uncommon Complications during Pregnancy
The most alarming complication during pregnancy is preeclampsia. It affects approximately 5% to 8% of pregnancies worldwide, which can cause fatal conditions for both the mother and the baby. The new findings now point out that sperm DNA damage may contribute to this condition, especially if it is due to assisted reproductive techniques such as IVF pregnancies. The research found that a DFI above 20% doubled the risk of preeclampsia from a mere 5% to almost 11% per.
Apart from causing preeclampsia, DNA fragmentation in sperm is also known to increase the risk for prematurity. Most premature babies experience respiratory, neurological, and developmental complications. Therefore, some degree of early intervention might be important for prospective parents.
Some of the rarer, though serious complications include placental abruption, which is the separation of the placenta from the uterine wall and intrauterine growth restriction, a condition by which the baby does not grow normally in the womb. These conditions though rare are potentially catastrophic both to the mother and the child. Results from this study may help in establishing the contribution of the father in such pregnancies.
Further study into sperm DNA damage is of urgent interest with regard to its consequences for pregnancy outcomes. According to Professor Aleksander Giwercman of Lund University in the field of Reproductive Medicine, "the analysis of DFI should be introduced as routine test in all fertility clinics.". "It could give answers to couples who are having difficulties with infertility, but our latest result also shows that DFI analysis can be a method to identify high-risk pregnancies, explained Giwercman.
For many, DNA fragmentation in sperm is often treatable. Common causes are oxidative stress, age, smoking, being obese, and infections. Addressing these elements will likely reduce DNA damage in sperm for men, raising the chances for a healthy pregnancy and baby.
Overall, the study importance should take into consideration paternal as well as maternal health towards reaching for a healthy pregnancy. Though DNA fragmentation in the sperm is supposed to increase the risk factors for complications in pregnancies, the advances into novel treatment approaches and tests are likely to alleviate complications in many families. Thus the findings of this study offer optimism and pave a pathway to more holistic fertility treatments in the future.
Credit: Canva
Every month, millions of women endure painful periods and convince themselves that it is normal. However, the statistics tell a different story. Endometriosis affects about 247 million women worldwide, and nearly 42 million of those are in India alone. Yet, most of them suffer in silence for years before they get diagnosed.
Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus, on the ovaries, fallopian tubes, bowel, or nearby pelvic areas. India accounts for nearly 25% of the global burden of this condition. Even with this staggering number, it remains one of the most underdiagnosed issues in women’s health.
- Pain severe enough to disrupt daily activities, work, or school
- Cramping that starts days before your period and continues after it ends
- Pain during or after intercourse
- Painful bowel movements or urination around your cycle
- Heavy or irregular bleeding
- Unexplained fatigue, bloating, or lower back pain
These are your body's warnings, not signs of weakness or something to just endure.
The Cost of Waiting
The statistics on diagnostic delays are alarming. On average, there is a 7 to 9-year delay between the first symptoms and a confirmed endometriosis diagnosis worldwide. Endometriosis affects 10–15% of all women of reproductive age and up to 70% of women with chronic pelvic pain, yet many spend nearly a decade seeing multiple doctors before anyone identifies the true cause.
This delay leads to serious consequences. The monthly natural conception rate in women with endometriosis drops to just 2–10%, compared to 20% in women without the condition. Longer delays are directly linked to more severe disease, greater psychological distress, and tougher fertility challenges.
Too many women come to me after years of being told their pain is normal. By the time they reach us, many are already dealing with advanced-stage disease.
Your pain is real, and it deserves a real answer. Do not wait, consult a specialist. Early diagnosis truly changes everything.
If your periods are affecting your quality of life, your body is asking you to listen. The sooner you seek help, the better your outcomes. Consult a specialist today. Take the first step towards a pain-free life.
Credit: iStock
India, which carries the world's second-largest population of hemophilia cases—a genetic blood disorder—must shift towards prophylaxis care for the bleeding disorder, said health experts today on the occasion of World Hemophilia Day.
World Hemophilia Day is observed every year on April 17 to raise global awareness of hemophilia and other inherited bleeding disorders.
This year’s theme of “Diagnosis: First step to care” highlights the critical importance of diagnosis—the essential first step in treatment and care.
According to the World Federation of Hemophilia (WFH), 75 percent of people suffer from hemophilia, without even knowing it, simply because they don’t have access to basic healthcare.
Hemophilia is a rare bleeding disorder where blood does not clot properly, even for minor injuries. It is caused by an error in a specific gene on the X chromosome, leading to a deficiency or absence of clotting factors.
While the condition mainly affects males, women are the genetic carriers. In people with hemophilia, the blood lacks sufficient clotting factors -- which are proteins essential for stopping bleeding.
Whether the bleeding is external, such as cuts, or internal, such as bleeding into joints or muscles, the blood does not clot. So, it can be a very serious disorder.
Without consistent care, repeated bleeding into joints can lead to
Hemophilia is mainly of three types:
Hemophilia A, the most common type, affects about 1 in 5,000 male births, underscoring the urgent need for improved detection and awareness.
Hemophilia B, on the other hand, is an X-linked genetic disorder affecting 1 in approximately 25,000 male births.
India bears a significant burden from Hemophilia A. Estimates suggest around 136,000 individuals are affected, but only a small fraction are diagnosed and registered due to unequal access to essential care.
Dr. Varun Kaul, Professor, Dept of Pediatrics, Guru Gobind Singh Medical College & Hospital, Faridkot, told HealthandMe that in India, systemic gaps, ranging from limited diagnostic access to unevenly distributed treatment centers, continue to restrict access to RRT, especially beyond metro cities.
In contrast, more than 50 per cent of persons with hemophilia globally benefit from regular replacement therapy (RRT) as the standard of care.
Routine replacement therapy (RRT), commonly known as prophylactic care or prophylaxis, is the standard treatment for severe hemophilia.
It involves the regular intravenous (IV) infusion of clotting factor concentrates to maintain factor levels above 1 per cent to prevent spontaneous bleeding, particularly into joints and muscles.
Most Indian patients currently rely on reactive, on-demand therapy to manage bleeds after they happen.
Dr. Kaul said that although this may help prevent the immediate crisis, it fails to stop the cumulative joint damage that often results in permanent disability.
“Providing regular, scheduled infusions to maintain sufficient clotting factor levels can prevent bleeds entirely, reducing annual bleed rates by 90 per cent and enabling a life free from chronic pain and constant fear of the next bleed,” Dr. Kaul said.
Some progress is visible, as States like Karnataka, Kerala, Jammu and Kashmir, to name a few, have pioneered state-sponsored RRT programs.
“It is now imperative to transition from mere crisis management toward implementing preventive care as a National Health priority,” Dr Kaul added.
Dr Rahul Bhargava, Principal Director & Chief - Hematology, Hemato-Oncology & Bone Marrow Transplant, Fortis Memorial Research Institute, Gurugram, stressed the importance of focusing the treatment on females.
"Carrier testing in hemophilia remains largely focused on affected males, while women who may be carriers are often not included in routine screening,” Dr Bhargava told HealthandMe.
As an X-linked inherited disorder, hemophilia can present in women with low clotting factor levels, leading to
Most of the cases remain undiagnosed until a clinical event occurs.
"Identifying carriers through timely testing enables appropriate counselling and informed reproductive decisions. It also supports early diagnosis in families and reduces the risk of severe bleeding complications in future generations,” the doctor said.
Dr Tulika Seth, Professor of Haematology at All India Institute of Medical Sciences (AIIMS) in New Delhi, in a post on social media platform X, stressed the importance of testing for hemophilia.
"If a child gets prolonged bleeding from a minor cut or injury, or if there are spontaneous painful swellings in the joints after minor falls, or sometimes even by somebody holding the baby, or there's a lot of bruising, people should get the baby tested or the adult tested for hemophilia," Dr. Seth said.
She noted that in mild cases of hemophilia, sometimes a person may not be aware that they have a deficiency, and then when they go for a tooth extraction or any surgery, they may have a problem.
"So, it's important to know your family history, and if you've had any prolonged bleeding after any pain, then you should tell your doctor and get tested," the doctor said.
Dr Bhargava also called for a broader approach that includes women in screening programs to help strengthen prevention and long-term management of hemophilia across families.
Hemophilia management requires attention beyond hospital care to prevent long-term complications.
To reduce bleeding episodes, it is important to:
Other measures include
"Integrating medical treatment with lifestyle practices supports functional independence and improves overall disease control,” Dr. Bhargava told HealthandMe.
Credit: Canva
Hemophilia is a rare genetic bleeding disorder, usually inherited, wherein blood cannot clot properly due to low levels of clotting factors, causing prolonged bleeding or spontaneous internal hemorrhages.
Symptoms include easy bruising, joint pain/swelling, and excessive bleeding. While not curable, it is treated with factor replacement therapy and gene therapy.
India has the world's second-largest population of hemophilia patients, with estimates suggesting over 70,000 to over 1,36,000 cases of Hemophilia A and B. However, while around 13,000 to 19,000+ patients are registered, many remain undiagnosed.
This World Hemophilia Day, Dr. Sheikh Bilal, Head of Department, Pathology, Government Medical College, Srinagar, Kashmir, exclusively told Healthandme that the primary reason why thousands of Indians remain undiagnosed and unable to access proper care is due to budget constraints, lack of awareness among policymakers, and the need for technocrats to advocate boldly for regular replacement therapy.
Despite having the second-largest hemophilia population, only 9-10 percent receive treatment as compared to 80-100 percent in some European countries.
The expert explained: "Money plays an important role. Every center in India has, at their own level, their own policymakers and the people who are at the helm of affairs. We are the second home for the hemophilia and we can change the lives of these people by having the regular replacement but it is all depending upon the perception of individual centers."
He also noted that the government needed to introduce policy reforms endorsing regular replacement therapy as the gold standard to help ensure equitable access to patients.
The median age at diagnosis for severe hemophilia in India stands at 60 months—five full years—compared to under 12 months in high-income countries. This delay is not just a matter of time but one that poses a risk of serious clinical consequences. Late diagnosis often means repeated, unmanaged bleeding episodes during early childhood, particularly into joints, before appropriate treatment begins.
The three types of this condition include :
The treatments for haemophilia have never been more effective, but they work only for patients who have been diagnosed. In a condition where every missed bleed moves a joint closer to permanent damage, the most important clinical act is also the most basic one: recognition.
The main treatment for severe hemophilia involves replacing the clotting factor you need through a tube in a vein. This replacement therapy can be given to treat a bleeding episode in progress. It can also be given on a regular schedule at home to help prevent bleeding episodes. Some people receive continuous replacement therapy.
Replacement clotting factor can be made from donated blood. Similar products, called recombinant clotting factors, are made in a laboratory, not from human blood.
© 2024 Bennett, Coleman & Company Limited